Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900213 | 1.00 | MAPT (0.45) | MAPTUBE2MDCUN1D1FAAHNPC1 | |
| SCHEMBL900395 | 0.83 | UBE2M (0.49) | MAPTUBE2MDCUN1D1FAAHNPC1 | |
| SCHEMBL900396 | 0.83 | UBE2M (0.49) | MAPTUBE2MDCUN1D1FAAHNPC1 | |
| SCHEMBL900311 | 0.75 | MAPT (0.56) | MAPTFAAHNPC1RAB9AKMT2A | |
| SCHEMBL900538 | 0.72 | RAB9A (0.49) | MAPTNPC1RAB9ADRD2SMN1; SMN2 | |
| SCHEMBL900539 | 0.72 | RAB9A (0.49) | MAPTNPC1RAB9ADRD2SMN1; SMN2 | |
| SCHEMBL900712 | 0.70 | CYP2D6 (0.43) | MAPTRAB9ALTA4HDRD3EBP | |
| SCHEMBL899810 | 0.70 | MAPT (0.43) | MAPTNPC1RAB9ALTA4HEBP | |
| SCHEMBL2720018 | 0.66 | CYP2D6 (0.42) | MAPTRAB9ALTA4HDRD3EBP | |
| SCHEMBL16822332 | 0.66 | MAPT (0.40) | MAPTNPC1RAB9ALTA4HEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621916-B1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2016-02-10 | — | — | EP | disclosed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| EP-2447263-A1 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | MAPT 2901/4885UBE2M 3664/4885DCUN1D1 3863/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | MAPT 3180/4885UBE2M 4320/4885DCUN1D1 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.